Tablets " ^{Allergosanum ®} " are appointed to adults and children is more senior than 12 years for relief of symptoms connected with:

• allergic rhinitis;
• small tortoiseshell.

Structure

Active ingredient - dezloratadin (one tablet supports a dezloratadin of 5 mg).

Excipients: microcrystalline cellulose, calcium hydrophosphate a dihydrate, starch corn, a gipromeloza, talc, the sodium stearylfumarating, silicon dioxide colloidal waterless; film covering: Opadray ІІ 33G 205005 blue (gipromeloza, lactoses monohydrate, titan dioxide (E 171), macrogoal 3350, triacetin, indigo carmine aluminum varnish (E 132), quinolinic yellow aluminum varnish (E 104)).

Contraindication

Hypersensitivity to active agent or to any of excipients of medicine or to a loratadin.

to Apply

orally, irrespective of meal.

to Adults and children is more senior than 12 years: about one tablet of 1 times a day, irrespective of meal, for elimination of the symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and a small tortoiseshell is recommended.

Therapy of intermittent allergic rhinitis (existence of symptoms less than 4 days a week or less than 4 weeks) needs to be carried out by

taking into account data of the anamnesis: to stop after disappearance of symptoms and to restore after their repeated emergence.

needs to continue by

In persistent allergic rhinitis (existence of symptoms more than 4 days a week or more than 4 weeks) treatment during the entire period of contact with allergen.

Pregnant

Dezloratadin did not show to

Feature of application

Dezloratadin gets into breast milk therefore its application is not recommended to women who nurse.

Children

Exist limited data of clinical trials of efficiency of application of a dezloratadin for teenagers from 12 to 17 years.

established data on efficiency and safety of application of a dezloratadin for children up to 12 years.

In clinical trials during which estimated ability to steer motor transport no deteriorations at the patients accepting dezloratadin are revealed

. However patients should be informed that very seldom some people test drowsiness that can affect their ability to drive the car and a difficult technique.

to

Overdose

At overdose the side reactions are similar to those which were observed in therapeutic doses, but manifestations can be stronger.

Symptoms. In clinical trials in which dezloratadin entered up to 45 mg (that by 9 times was exceeded by recommended) in doses clinically significant undesirable reactions were not observed.

Treatment. In case of overdose it is necessary to take standard measures for removal of not adsorbed active agent. The symptomatic and supporting treatment is recommended. Dezloratadin does not leave by a hemodialysis; the possibility of its removal at peritoneal dialysis is not established.

Side effects

Most often, in comparison with placebo, it was reported about such side reactions as increased fatigue (1.2%), dryness in a mouth (0.8%) and a headache (0.6%).

to Store

at a temperature not above 25 °C, out of children's reach.

Expiration date - 2 years.